Rite Aid R.Ph.s to raise funds for ADA
September 18th 2006Rite Aid pharmacists will lead teams of walkers this fall in the American Diabetes Association?s ?America?s Walk for Diabetes.? Rite Aid teams will participate in markets where the company is located to raise funds and help find a cure for diabetes.
Flu vaccine supply up from last year
September 18th 2006CDC has announced that 100 million doses of influenza vaccine will be manufactured for the upcoming season, more than any previous year. Almost all of the vaccine is expected be shipped in October and November, and new policies are in place this year that are designed to deliver at least some of the vaccine by the end of October to all the providers who placed orders.
Report finds mixed feelings around antibiotic use
September 18th 2006A new report from market research firm Decision Resources, entitled Antibiotics: Reaction of PCPs, Pediatricians, and Managed Care to Major Patent Expiries and New Products, has found that the expected FDA approval of faropenem medoxomil, the first oral penem antibiotic, triggered mixed feelings regarding its usefulness among healthcare providers surveyed.
New findings on Januvia bode well for approval
September 18th 2006Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Januvia, Merck), currently under review by the FDA, can cause a 2.1 percentage point drop in A1c levels in patients receiving the drug in conjunction with metformin, according to study results released at the 42nd Annual Meeting of the European Association for the Study of Diabetes this week.
Task force issues report on safe sedation practices
September 18th 2006Almost 70% of minor surgeries are now performed in surgical centers, physicians' offices, and hospital outpatient departments. Procedures including cardiac catheterizations and colonoscopies can be done using sedatives such as midazolam and fentanyl instead of general anesthesia.
ASCO updates guidelines on use of CSFs
September 18th 2006The American Society of Clinical Oncology (ASCO) recently updated its guidelines for the use of hematopoietic colony-stimulating factors (CSFs). The 2005 update committee unanimously agreed that the reduction in febrile neutropenia (FN) was an important clinical outcome that justified the use of CSFs, regardless of impact on other factors, when the risk of FN was approximately 20% and no other equally effective regimen that did not require CSFs was available. The first guidelines were published in 1994, and they were updated in 1996, 1997, 2000, and, most recently, 2005.
JCAHO seeks hospitals to test psychiatric measures
September 18th 2006The Joint Commission on Accreditation of Healthcare Organizations is looking for a few good hospitals. A few good psychiatric hospitals, that is. JCAHO is rolling out its first-ever hospital-based performance measures for inpatient psychiatric care for a year-long trial run starting in January 2007. Final measures will be released in October 2008.
Pharmacist intervention benefits diabetic patients
September 18th 2006Data from a new study funded in part by the Agency for Healthcare Research & Quality (AHRQ) revealed a robust reduction in patients' blood sugar levels when pharmacists or nurses were utilized as case managers who made independent decisions regarding medication use instead of waiting for physician approval.
FDA puts compounding pharmacies on hot seat
September 18th 2006The Food & Drug Administration recently issued letters to three pharmacies warning them to "stop manufacturing and distributing thousands of doses of compounded, unapproved inhalation drugs nationwide." The three named companies, RoTech Healthcare, CCS Medical, and Reliant Pharmacy Services, were all warned that if they did not comply, they risked injunctions and the possible seizure of their products in question.
Managing hyperglycemia in Type 2 diabetes: Here's how
September 18th 2006The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recently created a consensus statement on the management of hyperglycemia in patients with Type 2 diabetes. "This is a consensus document that is supported by evidence from clinical trials. Some of the recommendations are based on expert opinion, but this is true for any guideline. These guidelines will likely be useful to pharmacists and nurses because many times their practice is driven by guidelines," stated Stuart Haines, Pharm.D., FCCP, FASHP, professor and vice chair for education at the University of Maryland school of pharmacy.
New guide addresses valvular heart disease
September 18th 2006Managing patients with valvular heart conditions can be a real challenge. They often require lifelong monitoring, with replacement surgery and subsequent anticoagulation. Recently, in a joint effort, the American College of Cardiology (ACC) and the American Heart Association (AHA) revised their 1998 recommendations to create the ACC/ AHA 2006 Practice Guidelines for the Management of Patients with Valvular Heart Disease. The executive summary and recommendations were published in the Aug. 1, 2006, issues of the Journal of the American College of Cardiology and Circulation.
Hepatitis C treatments show early promise
September 18th 2006For a disease that affects an estimated 3.9 million Americans, the treatment of choice works only about 50% of the time for patients with genotype 1, the most common type of hepatitis C virus (HCV) found in the United States, according to the Centers for Disease Control & Prevention. Sustained response rates are slightly higher in genotypes 2 and 3 (up to 80%).
Updated guidelines target treatment of STDs
September 18th 2006In an effort to improve the care of patients with sexually transmitted diseases (STDs), the Centers for Disease Control & Prevention recently updated its STD guidelines. The update is an evidence-based document, the result of experts' evaluation of the medical literature since the previous publication of Sexually Transmitted Diseases Treatment Guidelines in 2002.
R.Ph.s support Plan B's new pharmacy-only status
September 18th 2006The pharmacy community seems to be solidly behind the Food & Drug Administration's move to switch Duramed Pharmaceuticals' Plan B (levonorgestrel) emergency contraception to over-the-counter status. In giving the green light, the FDA granted OTC status for consumers 18 years of age and older, while maintaining the prescription status for girls 17 and younger.
Pharmacists want federal drug pedigree standard
September 11th 2006A majority of pharmacists want an overarching federal approach to drug pedigree laws, according to an Instant Poll on Drug Topics' Web site, posted in August. Fifty-six percent of the 538 voters stated that they preferred a standard law across the country to a patchwork of state laws.
Work group studying how to measure R.Ph.s' performance
September 11th 2006A Pharmacy Quality Alliance work group is drafting a starter set of measures to evaluate pharmacy performance under Medicare Part D. This is a part of CMS' pay-for-performance approach, under which health plans would pay pharmacists who perform according to metrics identified by industry stakeholders.
FDA asks U.S. marshals to seize dietary supplements
September 11th 2006On Sept. 5, U.S. marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advance Arthritis Support capsules distributed by Advantage Nutraceuticals LLC of Fort Walton Beach, Fla., valued at about $55,000. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
New diabetes treatment combines two drugs into one
September 4th 2006As the saying goes, two are better than one. And that's just what Takeda Pharmaceuticals is saying about its new combination drug recently approved by the Food & Drug Administration. Duetact takes pioglitazone (Actos, Takeda)-a thiazolidinedione-and adds glimepiride-a sulfonylurea-in an effort to offer Type 2 diabetes patients a new, once-daily alternative.